Objectives: To determine the susceptibility of Gram-negative anaerobic bacteria of the family Bacteroidaceae from hospitalized patients with intra-abdominal infections (IAIs) to moxifloxacin and other antimicrobial agents with known activity against anaerobes.
Introduction
Bacteria of the Bacteroides fragilis group are the anaerobic pathogens that are most frequently recovered from patients with intra-abdominal infections (IAIs). Antimicrobial susceptibility varies considerably among the different species in this group, 1 -3 yet most diagnostic laboratories do not routinely identify these organisms to species level nor determine antimicrobial susceptibilities because susceptibility testing of anaerobes is notoriously difficult and time-consuming. Empirical antimicrobial therapy of infections involving anaerobes such as IAIs usually includes an agent with known efficacy against anaerobes, 4 based on patterns of susceptibility derived from published reports and surveillance studies. Resistance among anaerobes to antimicrobials has increased since the early 1980s and currently includes even those antibiotics that were previously thought to be universally active, such as piperacillin/tazobactam, the carbapenems and metronidazole. 5 In particular, increasing resistance of the B. fragilis group to clindamycin, cefoxitin, piperacillin/tazobactam and the carbapenems, as well as trovafloxacin and moxifloxacin, has been noted. 1 -3,5 -7 The rates of resistance show clinically important variations between countries and may also vary from one medical centre to another within a country. 1 -3,7,8 Periodically monitoring local and national susceptibility patterns has therefore been recommended to guide empirical therapy. 1, 4 Among the new fluoroquinolones, moxifloxacin and trovafloxacin are characterized by enhanced activity against anaerobes, including the Bacteroides fragilis group and other Gram-negative anaerobic bacilli involved in IAIs. 9 In two prospective, randomized, double-blind studies and in one open-label study, moxifloxacin monotherapy was shown to be as effective and safe as combination therapy with ceftriaxone plus metronidazole or piperacillin/tazobactam, respectively, for the treatment of IAIs. 10 -12 The aim of the multicentre Prospective In Vitro Study to Determine the Activity of Moxifloxacin against Isolates from Patients with Abdominal Infection (PRISMA study) was to determine the antimicrobial activity of moxifloxacin and six other antimicrobial agents against contemporary anaerobe Gram-negative bacterial isolates of the family Bacteroidaceae from patients with documented IAIs.
Materials and methods

Bacterial isolates
A total of 430 non-duplicate Gram-negative anaerobic bacterial isolates of the family Bacteroidaceae from patients with community-onset or hospital-onset IAIs were prospectively collected from 32 centres (including 24 university hospitals and 8 primary care hospitals) in Germany in 2007. Patients' age ranged from 1 to 93 years (mean age, 55 years; median age, 59 years), and the majority of patients (79%) were treated at tertiary care referring hospitals and on regular wards (72%) versus intensive care units (ICUs) (28%). Infections included: appendicitis (n ¼158); intra-abdominal abscess (n¼100); peritonitis (n¼79); biliary tract infections (n¼35); diverticulitis (n¼28); intra-abdominal fistula (n ¼19); pancreatitis (n ¼6); and liver or spleen abscess (n ¼5). Specimens qualifying for this study included swabs from the intra-abdominal cavity obtained during surgery, intra-abdominal biopsies, abscess fluid, ascitic fluid, drainage fluid and blood cultures. Each centre was encouraged to submit 20 isolates of the family Bacteroidaceae. Identification to genus level was performed using routine methodology at the participating laboratories. Isolates were referred to the Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, for species identification and susceptibility testing. Species identification was done at the central laboratory using the RapID TM ANAII system (Remel, Lenexa, KS, USA).
Antimicrobial susceptibility testing
Broth microdilution was performed at the central laboratory according to the German DIN (Deutsches Institut fü r Normung) 58940-83 guidelines with Wilkens-Chalgren broth (Haipha, Heidelberg, Germany). 13 Microtitre plates containing dehydrated antimicrobial agents were provided by Merlin Diagnostica (Bornheim-Hersel, Germany). The antimicrobial agents and concentration ranges tested in 2-fold steps were: ampicillin/sulbactam, 0.062/4-128/4 mg/L; ertapenem, 0.031 -64 mg/L; meropenem, 0.031-64 mg/L; levofloxacin, 0.015 -32 mg/L; moxifloxacin, 0.015-32 mg/L; clindamycin, 0.015-32 mg/L; and metronidazole, 0.031-64 mg/L. Plates were incubated for 48 h at 378C in an anaerobic chamber (Anoxomat TM system, Mart Microbiology, Drachten, The Netherlands). B. fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741 were used as quality control strains and tested each time an anaerobic susceptibility test was performed. Clinical breakpoints for interpretation of susceptible and resistant isolates, respectively, were those defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for b-lactams, clindamycin and metronidazole: ampicillin/sulbactam, ≤4/4 and .8/4 mg/L; ertapenem, ≤1 and .1 mg/L; meropenem, ≤2 and .8 mg/L; clindamycin, ≤4 and .4 mg/L; and metronidazole, ≤4 and .4 mg/L.
14 Since no EUCAST breakpoints are available for moxifloxacin, the breakpoints recommended by the CLSI, ≤2 and .4 mg/L, were used. 15 As anaerobes are a poor target for therapy with levofloxacin, susceptibility testing is not recommended by the EUCAST and CLSI, and this compound was only tested for comparison. Table 1 summarizes the distribution by species of the 430 Gramnegative anaerobe bacterial isolates included, and the MIC distributions and in vitro susceptibilities to the seven antimicrobial compounds tested. The most frequently isolated species among the Bacteroides spp. was B. fragilis (n¼ 238 isolates; 55.3%), followed by B. thetaiotaomicron (n¼ 79; 18.4%), Bacteroides uniformis (n¼ 33; 7.7%), Bacteroides vulgatus (n¼ 22; 5.1%), Parabacteroides (previously Bacteroides) distasonis (n¼ 16; 3.7%), Bacteroides ovatus (n¼ 10; 2.3%) and other Bacteroides spp. (n¼ 11; including Bacteroides caccae, 3; Bacteroides eggerthii, 2; Bacteroides merdae, 1; Bacteroides splanchnicus, 1; and non-specified Bacteroides spp., 4; 2.6%). Twenty-one isolates (4.9%) were identified as Prevotella spp. (Prevotella bivia, 7; Prevotella oralis, 6; Prevotella loescheii, 3; Prevotella oris, 2; Prevotella buccae, 1; Prevotella disiens, 1; and Prevotella melaninogenica, 1).
Results
Almost all of the Bacteroides and Prevotella isolates studied were susceptible to metronidazole. Only three B. fragilis isolates (1.3%) and one B. uniformis isolate (3%) were resistant to metronidazole (MIC, 32 mg/L). Likewise, most of the anaerobes studied were susceptible to the carbapenems; however, up to 8% of the B. fragilis isolates were resistant to both carbapenems tested, with MICs as high as ≥128 mg/L, as were 6.2% of the P. distasonis isolates and 2.5% of the B. thetaiotaomicron isolates. All but two of the Prevotella spp. isolates were susceptible to moxifloxacin. However, 10% -22% of the P. distasonis, B. fragilis, B. ovatus, B. thetaiotaomicron and B. uniformis isolates were resistant to moxifloxacin, as were 59% of the B. vulgatus isolates. In terms of MICs, moxifloxacin was four times more active than levofloxacin.
Most of the isolates studied (65%-85%) were obtained from patients admitted to a tertiary care hospital, so that the absolute numbers of isolates from primary care patients per species were too small to allow statistical analysis. Nevertheless, there was a trend towards higher resistance rates among isolates obtained from tertiary care patients. For example, 185 B. fragilis isolates were recovered from tertiary care patients; 7.5%, 9.2% and 8.7% of these were resistant to ampicillin/sulbactam, ertapenem and meropenem, respectively, whereas 1.9%, 3.8% and 3.8% of the strains isolated from primary care patients (n ¼53) were resistant to ampicillin/sulbactam, ertapenem and meropenem, respectively. The moxifloxacin resistance rates were 15.1% versus 9.4% for the B. fragilis and 23.4% versus 13.3% for the B. thetaiotaomicron isolates recovered from these two patient groups.
The same trend was observed for anaerobes isolated from ICU versus standard care patients (data not shown).
Discussion
Confirming previous studies from the USA and from various European countries, the present study shows the variability of resistance patterns among Gram-negative anaerobe bacterial Seifert et al. 
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German survey of susceptibility of Bacteroidaceae causing intra-abdominal infections isolates of the family Bacteroidaceae. Although the rates of resistance show clinically important differences between continents and countries, several surveillance studies have demonstrated that for the last two decades there has been a global trend towards decreasing activities of anti-anaerobic agents of almost all drug classes, i.e. the b-lactams including the carbapenems, clindamycin, the quinolones and even metronidazole against species of the B. fragilis group. 1 -3,5 -8 While resistance to metronidazole in the USA has only recently been observed, with three metronidazole-resistant isolates detected among 6574 isolates recovered between 2002 and 2007, 5 resistance to metronidazole has been more frequently observed in some European countries, such as Belgium (1% resistance among 238 isolates of the B. fragilis group) and Greece (1% resistance among 296 isolates of the B. fragilis group). 7, 16 Two isolates (1.2%) resistant to metronidazole (1 isolate each of B. fragilis and B. thetaiotaomicron) were also reported in a recent European survey. 8 Resistance to metronidazole was not detected among 1343 isolates of the B. fragilis group in a recent survey from Spain. 2 In the present study, resistance to metronidazole was observed in one B. uniformis isolate and three B. fragilis isolates having high MICs, accounting for a resistance rate of 1% among the B. fragilis group also in Germany.
Increasing resistance to the carbapenems among the B. fragilis group is a cause of concern. The resistance rate among B. fragilis observed in the present study was alarmingly high, with 8% for ertapenem and 7.5% for meropenem. These rates are comparable only to data from a recent survey from Taiwan (5%), 8 but they are considerably higher than those reported from other European countries, such as Belgium (1%), Greece (1%) and Spain (0.6%). 2, 6, 7, 16 In contrast, in the USA, resistance to carbapenems has recently decreased and is currently estimated at 0.4% -1%. 3 Our data support the continuing trend towards increasing resistance of the B. fragilis group to moxifloxacin, as demonstrated in the US survey as well as in Belgium, Greece and Spain. 2, 3, 7, 16, 17 This may appear surprising because previous fluoroquinolones, such as norfloxacin, ofloxacin, ciprofloxacin and levofloxacin, were not used clinically for treatment of anaerobic infections. Surveillance testing in the USA performed between 1994 and 1996 revealed that quinolone resistance ranged between 3% and 8% and since then has increased to approximately 30% -40%, and exceeded 50% in isolates of B. vulgatus. 5 Resistance rates in our study were lower, ranging from 10% to 22% for the different species of the B. fragilis group, but were comparable for B. vulgatus.
In four European countries (Iceland, the Netherlands, Greece and Poland) no isolates resistant to moxifloxacin were detected, whereas in Germany (12%), Spain (15%), France (16%), the UK (22%) and Belgium (27 -40%) moxifloxacin resistance was more frequently observed. 1, 7 These differences may in part be attributed to the different patient populations investigated (nosocomial versus community-acquired infections; tertiary versus primary care centres; ICU versus standard care), to the extent of quinolone use in general in these countries and to the use of different methods and breakpoints for interpretation. We used broth microdilution in the present study, although unlike for other antimicrobials such as ampicillin/sulbactam, ertapenem, clindamycin and metronidazole, there are as yet no data showing that moxifloxacin MIC values determined by agar and broth microdilution can be considered equivalent. In fact, we observed a trend for higher moxifloxacin MICs among the most prevalent species, B. fragilis and B. thetaiotaomicron, obtained from tertiary versus primary care centres and from ICU versus standard care patients. However, the numbers of isolates per subgroup were too small to allow statistical analysis. Also, data on the previous use of antimicrobials in these patients were not available.
In conclusion, this survey represents the most comprehensive report on the susceptibility patterns of the major anaerobic pathogens causing IAIs in Germany. Although metronidazole, the carbapenems and b-lactamase/b-lactamase inhibitor combinations remain useful agents for the therapy of IAIs, resistance to these compounds was observed and the surprisingly high rate of carbapenem resistance has significant therapeutic implications. Our data support recent clinical findings that moxifloxacin plus adequate source control could be an appropriate treatment of IAIs. 4,10 -12 These data also emphasize the need not only for periodic monitoring of the susceptibility patterns of anaerobic pathogens at the national and institutional levels to guide empirical treatment but also for species identification and susceptibility testing in selected groups of individual patients, because susceptibility has been shown to be related to outcome in these infections. 18 
